文献速递妇科生殖医学

围手术期:一个减少子宫内膜异位症复发风险的关键却常被忽视的时间窗?

The perioperative period: a critical yet neglected time window for reducing the recurrence risk of endometriosis?
PubMed 文献 · Hum Reprod · 2019-01-01

本文是一篇叙述性综述,指出子宫内膜异位症术后复发是严峻挑战,复发多源于微小残留病灶而非新发病灶。现有防复发努力集中在术后激素药物,而围手术期因素可能通过抑制细胞免疫 disproportionately 影响复发风险,且可能可干预。作者呼吁研究围手术期使用β受体阻滞剂和/或NF-κB/COX-2抑制剂等干预措施以降低复发风险。

要点

  • 术后复发是子宫内膜异位症管理的严峻挑战,重复手术增加卵巢早衰、粘连和器官损伤风险。
  • 复发更可能源于微小残留病灶而非新发病灶。
  • 围手术期因素可能通过激活肾上腺素能信号和释放前列腺素抑制细胞免疫,促进复发。

核心结论

  • 围手术期可能对子宫内膜异位症复发风险有不成比例的高影响,且可能可干预,但被普遍忽视。
  • 作者呼吁研究围手术期干预以降低子宫内膜异位症复发风险,潜在收益可能较传统术后干预大幅降低复发风险和成本。

研究设计与样本

  • 本文为叙述性综述,未进行系统检索,讨论围手术期因素与子宫内膜异位症复发风险的关系及潜在干预措施。

主要发现

  • 有证据提示复发性子宫内膜异位症病变更可能源于微小残留病灶而非新发病灶。
  • 许多围手术期因素已知或可设想通过激活肾上腺素能信号和释放前列腺素抑制细胞免疫,从而促进子宫内膜异位症复发。
  • 围手术期使用β受体阻滞剂和/或NF-κB/COX-2抑制剂可能增强被手术抑制的细胞免疫,导致微小残留病灶部分或完全清除并降低复发风险。

关键数值与推荐

  • 目前对抗复发的努力大多集中于术后使用激素药物,通过病灶休眠和可能萎缩来降低复发风险。

临床怎么用

  • 作者提出围手术期使用β受体阻滞剂和/或NF-κB/COX-2抑制剂可能降低复发风险,该假设有生物学合理性并得到近期实验研究支持。
  • 作者呼吁开展更多关于围手术期干预以降低子宫内膜异位症复发风险的研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

While surgery is commonly the management of symptomatic endometriosis when patients do not respond to medical or supportive therapy, recurrence after surgery poses a serious challenge, and repeat surgery increases the risk of premature ovarian failure, adhesion and organ injury. Conceivably, the recurrent endometriotic lesions could arise from minimal residual lesions (MRLs) or from de novo lesions. However, several lines of evidence suggest that the former is more likely. So far, most, if not all, efforts to combat recurrence have been focused on postoperative medication of hormonal drugs to reduce recurrence risk through lesional dormancy and possibly atrophy. However, the perioperative period may exert a disproportionally high impact on the risk of recurrence; it is likely to be amendable for possible intervention but has been generally neglected. Indeed, many perioperative factors are known to or conceivably could facilitate the recurrence of endometriosis through the suppression of cell-mediated immunity due to the activation of adrenergic signaling and the release of prostaglandins. Perioperative use of β-blockers and/or nuclear factor κB/jCycloxygenase 2 (NF-κB/COX-2) inhibitors may boost the cell-mediated immunity suppressed by surgery, resulting in the partial or even complete removal of MRLs and reduced recurrence risk. This is both biologically plausible and supported by a recent experimental study. We call for more research on possible perioperative interventions to reduce the recurrence risk of endometriosis. The potential payoff might be a substantial reduction in the risk of recurrence and cost when compared with the traditional approach of postoperative intervention.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Guo SW, Martin DC. The perioperative period: a critical yet neglected time window for reducing the recurrence risk of endometriosis? Hum Reprod. 2019. PMID: 31585460. doi:10.1093/humrep/dez187

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。